uniQure Announces Financial Results For Second Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress

~ Progress Across the Pipeline ~ Additional data on AMT-060 in Hemophilia B Expected Later this Year ~Data from Sanfilippo B and Parkinson’s Disease Studies Expected in Q1 2017 ~Strong Balance Sheet to Support Advancement of Programs

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 25, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leader in human gene therapy, today announced its financial results for the second quarter, ended June 30, 2016, and provided an update on corporate developments.

“We continue to make solid progress on our pipeline programs and are pleased to maintain a strong cash position that will enable us to advance our product candidates well into the future,” stated Daniel Soland, chief executive officer of uniQure. “We presented promising updated clinical data from the low-dose cohort of our ongoing Phase I/II study of AMT-060, which demonstrated durable, therapeutically relevant Factor IX activity in older patients with severe hemophilia B and advanced joint disease.  Importantly, we expect to present up to one year of follow-up data from our low dose cohort and up to 6 months of follow-up data from our second dose cohort of AMT-060 later this year.  Additionally, we look forward to clinical data presentations from studies in Sanfilippo B and Parkinson’s disease in the first quarter of 2017.”

Recent Corporate Highlights

Pipeline and Business Updates

Liver/Metabolic Diseases

  • Advancing AMT-060 in Hemophilia B – uniQure presented updated results from its ongoing Phase I/II clinical trial of AMT-060 in patients with severe hemophilia B and advanced joint disease at the World Federation of Hemophilia Congress. The clinical data from the low-dose cohort showed sustained Factor IX (FIX) activity and a substantial reduction in FIX usage. All patients had improvements in their disease phenotype and continued to maintain durable levels of FIX activity for up to 9 months post treatment.  Four out of five patients remained free of prophylactic FIX usage with mean steady-state FIX activity of 5.4% of normal and an 82% reduction in total FIX usage through up to 9 months.  Of note , AMT-060 continues to demonstrate a very low screening failure rate, with all patients screened in the study testing negative for pre-existing anti-AAV5 antibodies. All five patients in the second-dose cohort have now been treated, with 6-month data expected to be available for presentation later this year.    

Central Nervous System (CNS) Diseases

  • Ongoing Follow-up of AMT-110 in Sanfilippo B - uniQure anticipates that all four patients in this Phase I/II extension study will have completed their 30-month evaluation late this year and that clinical data will be presented in the first quarter of 2017.  uniQure assumed sponsorship of the Phase I/II study extension protocol earlier this year.
  • Advancing Preclinical Research of AMT-130 in Huntington’s Disease – uniQure is conducting ongoing IND-enabling studies of AMT-130 in non-human primates.  Earlier this year, uniQure published and presented data providing preclinical proof-of-concept and demonstrating the potential of a one-time administration of AAV5-delivered gene therapy to successfully silence the Huntingtin gene.
  • Continued Progress on Phase I/IIa Study of AMT-140 in Parkinson’s Disease – Two of the four, six-patient cohorts have now been fully enrolled since June 2016 in an ongoing Phase I/IIa clinical study of AMT-140, an AAV2-GDNF gene therapy for the treatment of Parkinson’s disease.  Top-line data, including safety, tolerability and preliminary efficacy results, are expected to be available for presentation in the first quarter of 2017.  The study is being conducted under the direction of Krystof Bankiewicz at the University of California, San Francisco (UCSF) and John Heiss at the National Institutes of Health.  uniQure has exclusive rights to GDNF in gene therapy and has the option to acquire the program from UCSF. 

Cardiovascular Diseases

  • Increasing Activity in Support of BMS Collaboration – uniQure and its collaboration partner, Bristol Myers Squibb (BMS), continue to conduct IND-enabling studies for S100A1, a proprietary gene therapy for chronic heart failure.  In addition to S100A1, uniQure and BMS have initiated work on 3 additional targets designated under their collaboration. 

Leadership Team and Board of Directors

  • Added Key Talent – In the second quarter, uniQure significantly strengthened its senior management team with the appointment of Paul Firuta as Chief Commercial Officer, Hans Janssen as Senior Vice President, Human Resources, Maria E. Cantor as Senior Vice President, Investor Relations & Communications, and Jonathan Garen as Chief Business Officer.
  • Completed Corporate Governance Changes – Following its Annual General Meeting in June, the Company transitioned from a two-tier Supervisory Board and Management Board to a single Board of Directors structure with executive and non-executive members. This new structure reflects corporate governance standards most familiar to the majority of the Company’s shareholder base. In addition, the Company appointed Jack Kaye, a seasoned financial executive with more than 40 years of diversified experience, to its Board of Directors.  Company shareholders also approved the appointments of Daniel Soland, chief executive officer, and Matthew Kapusta, chief financial officer, as executive directors of the Board.  Finally, as part of the governance transition, Mr. Ferdinand Verdonck and Mr. Joseph Fezcko retired from the board.

Business Development

  • In the second quarter, uniQure revised its existing license contract with Protein Sciences Corporation for the use of its expres SF+ (SF+) insect cell line to provide the Company with a royalty free, perpetual right and license to the licensed technology in the field of AAV-based gene therapy.

Financial Highlights for Q2 2016

As of June 30, 2016, the Company held cash and cash equivalents of €165.6 million, compared with of €203.5 million as of December 31, 2015, a decrease of €37.9 million. The decrease includes €36.4 million of cash used in operating, investing and financing activities during the six months ended June 30, 2016, in addition to a €1.5 million loss related to foreign currency effects on U.S. dollar-denominated deposits. The Company maintains its expectation that existing cash resources will be sufficient to fund operations into the second half of 2018.   

Licensing and collaboration revenues for the three months ended June 30, 2016 were €3.9 million, compared with €1.6 million for the comparable period in 2015. The increase relates to increased research activity associated with S100A1 for heart failure, which are fully reimbursed by BMS in accordance with the Company’s collaboration agreement.

Research and development expenses were €17.3 million for the three months ended June 30, 2016, compared with €10.6 million for the comparable period in 2015. The increase is mainly due to increased activity in support of our collaboration agreement with BMS, validation and scale-up activities related to AMT-060 in the Company’s Lexington facility, increased facility costs in Amsterdam and the continued progression of our gene therapy product candidates targeting Sanfilippo B, Huntington’s disease and hemophilia A.    

Selling, general and administrative expenses were €5.5 million for the three months ended June 30, 2016, compared with €4.5 million for the comparable period in 2015. The change is primarily related to an increase in personnel expense, as well as an increase in expenses associated with the Glybera global registry and Phase IV study, which are currently classified as selling, general and administrative expenses, but were previously capitalized in the same period in 2015 prior to the commencement of Glybera commercialization.

The net loss for the second quarter 2016 was €19.3 million, or €0.77 per share, compared with €18.9 million, or €0.87 per share, for the second quarter of 2015. The Company had 25,137,009 ordinary shares outstanding as of June 30, 2016.

About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor Direct: 339-970-7536 Mobile:  617-680-9452 m.cantor@uniQure.com

Eva Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com

 
UNIQURE N.V.
Unaudited Condensed Consolidated Statement of Financial Position
(€ in thousands)
 
    December 31,   June 30,
    2015       2016  
Assets        
Non-current assets        
Goodwill     442       442  
Intangible assets other than Goodwill     7,209       8,956  
Property, plant and equipment     23,820       24,041  
Other non-current assets     1,142       1,675  
Total non-current assets     32,613       35,114  
Current assets        
Receivables from related parties     3,792       1,502  
Trade and other receivables     1,730       5,195  
Inventories     435       363  
Cash and cash equivalents     203,532       165,646  
Total current assets     209,489       172,706  
Total assets       242,102         207,820  
Equity        
Share capital     1,216       1,257  
Share premium     344,803       346,732  
Other reserves     26,026       29,785  
Accumulated deficit     (252,561 )     (292,468 )
Total equity     119,484       85,306  
Liabilities        
Non-current liabilities        
Borrowings     13,434       18,356  
Derivative financial instruments - related party     530       136  
Deferred rent     5,737       5,789  
Deferred revenue     75,852       73,507  
Contingent consideration     2,687       2,915  
Total non-current liabilities     98,240       100,703  
Current liabilities        
Trade and other payables     11,220       12,568  
Derivative financial instruments - related parties     992       222  
Borrowings     5,124       -  
Borrowings - derivative     238       51  
Deferred rent     579       592  
Deferred revenue     6,225       5,978  
Provisions     -       2,400  
Total current liabilities     24,378       21,811  
Total liabilities       122,618         122,514  
Total equity and liabilities       242,102         207,820  
                 
UNIQURE N.V.
Unaudited Condensed Consolidated Statements of Comprehensive Income
(€ in thousands except share and per share data)
 
  Three months ended   Six months ended
  June 30,   June 30,
               
  2015       2016       2015       2016  
License revenues   492       1,101       713       2,202  
Collaboration revenues   1,123       2,840       2,009       5,641  
Total revenues     1,615         3,941         2,722         7,843  
Cost of goods sold   -       (76 )     -       (152 )
Other income   140       423       346       824  
Research and development expenses   (10,613 )     (17,335 )     (20,719 )     (32,463 )
Selling, general and administrative expenses   (4,509 )     (5,504 )     (8,668 )     (12,108 )
Other gains/(losses), net   (5,241 )     (321 )     (996 )     (4,379 )
Total operating costs     (20,223 )       (22,813 )       (30,037 )       (48,278 )
Operating loss     (18,608 )       (18,872 )       (27,315 )       (40,435 )
Finance income   46       64       65       1,584  
Finance expense   (325 )     (523 )     (4,275 )     (1,056 )
Finance income/(expense), net     (279 )       (459 )       (4,210 )       528  
Result before corporate income tax     (18,887 )       (19,331 )       (31,525 )       (39,907 )
Provision for income taxes   -       -       -       -  
Net loss     (18,887 )       (19,331 )       (31,525 )       (39,907 )
Items that may be subsequently reclassified to profit or loss              
Currency translation differences on foreign operations   (285 )     356       1,086       (301 )
Other comprehensive income/(loss)   (285 )     356       1,086       (301 )
Total comprehensive loss     (19,172 )       (18,975 )       (30,439 )       (40,208 )
Loss per share attributable to the equity holders of the              
Company during the period:              
Basic and diluted loss per share     (0.87 )       (0.77 )       (1.58 )       (1.60 )
                               
UNIQURE N.V.
Unaudited Condensed Consolidated Statements of Changes in Equity/Deficit
(€ in thousands)
                     
    Total                
    share   Share   Other   Accumulated   Total
    capital   premium   reserves   deficit   equity
Balance at January 1, 2015     905       206,111         17,149         (181,081 )       43,084  
Loss for the period   -     -       -       (31,525 )     (31,525 )
Other comprehensive income/(loss)   -     -       1,086       -       1,086  
Total comprehensive income/(loss)     -       -         1,086         (31,525 )       (30,439 )
Capital contributions   231     101,747       -       -       101,978  
Share issuance costs   -     (612 )     -       -       (612 )
Share based payment/expense   -     -       3,416       -       3,416  
Balance at June 30, 2015     1,136       307,246         21,651         (212,606 )       117,427  
Loss for the period   -     -       -       (39,955 )     (39,955 )
Other comprehensive income/(loss)   -     -       164       -       164  
Total comprehensive income/(loss)     -       -         164         (39,955 )       (39,791 )
Capital contributions   80     37,557       -       -       37,637  
Share based payment/expense   -     -       4,211       -       4,211  
Balance at December 31, 2015     1,216       344,803         26,026         (252,561 )       119,484  
Loss for the period   -     -       -       (39,907 )     (39,907 )
Other comprehensive income/(loss)   -     -       (301 )     -       (301 )
Total comprehensive income/(loss)     -       -         (301 )       (39,907 )       (40,208 )
Capital contributions   41     1,929       -       -       1,970  
Share based payment/expense   -     -       4,060       -       4,060  
Balance at June 30, 2016     1,257       346,732         29,785         (292,468 )       85,306  
UNIQURE N.V.
Unaudited Condensed Consolidated Statements of Cash Flows
(€ in thousands)
 
  Six months ended
  June 30,
       
    2015       2016  
Cash flow from operating activities      
Net loss   (31,525 )     (39,907 )
Adjustments for:      
Amortization on intangible assets   -       378  
Depreciation   1,877       2,462  
Lease incentive   333       (398 )
Loss/(gain) on derivatives   1,666       (1,351 )
Loss/(gain) on foreign exchanges   1,873       1,280  
Share-based expenses   3,416       4,060  
Changes in provisions   -       2,400  
Changes in trade and other receivables   (1,363 )     (1,174 )
Changes in inventories   (214 )     72  
Changes in other current liabilities   (232 )     810  
Changes in deferred revenue   52,769       (2,592 )
Cash generated from/(used in) operations     28,600         (33,960 )
Interest paid   (929 )     (1,006 )
Net cash generated from/(used in) operating activities     27,671         (34,966 )
Cash used in investing activities      
Purchases of intangible assets   (1,729 )     (10 )
Purchases of property, plant and equipment   (1,855 )     (2,776 )
Changes in restricted cash   -       (555 )
Interest received   59       33  
Net cash used in investing activities     (3,525 )       (3,308 )
Cash flow from financing activities      
Proceeds from shares issued   101,366       1,970  
Payments of finance lease   (82 )     (88 )
Net cash generated from financing activities     101,284         1,882  
Net increase/(decrease) in cash and cash equivalents     125,430         (36,392 )
Currency effect cash and cash equivalents   3,206       (1,494 )
Cash and cash equivalents at January 1   53,219       203,532  
Cash and cash equivalents at June 30     181,855         165,646  
               

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading